APOE and endothelial dysfunction: A-FABP could reduce the insulin-dependent nitric oxide synthase (NOS) expression in human umbilical vascular endothelial cells [19], while A-FABP inhibitor improves endothelial dysfunction in old ApoE-deficient mice [20].